Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alana Upthagrove"'
Autor:
W. Griffith Humphreys, Alana Upthagrove, Zhaopie Zeng, Bo Wen, Chandra Prakash, Suresh K. Balani, Heng-Keang Lim, Weichao Chen, Sekhar Surapaneni, Donghui Cui, Anthony J. Lee, Susanna Tse, Christopher MacLauchlin, Ling He, Jialin Mao, Robert L. Walsky, W. George Lai, Hongbin Yu
Publikováno v:
Drug Metabolism and Disposition. 43:620-630
Recent European Medicines Agency (final) and US Food and Drug Administration (draft) drug interaction guidances proposed that human circulating metabolites should be investigated in vitro for their drug-drug interaction (DDI) potential if present at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d2cf1c4ea6b879d4785b1d10476993d
https://doi.org/10.1124/dmd.114.059345
https://doi.org/10.1124/dmd.114.059345
Autor:
Wai-Si Eng, Xinchun Tong, Richard Tschirret-Guth, Song Zheng, Gary G. Chicchi, Geoge A. Doss, Koppara Samuel, Richard Hargreaves, Terence G. Hamill, Marc M. Kurtz, Robert J. DeVita, Sanjeev Kumar, Alan Wheeldon, Emma J. Carlson, Alana Upthagrove, Jaime Lynn Bunda, Stephen Krause, Jinlong Jiang, Christine Ryan, Sander G. Mills, Donald Burns, Kwei-Lan C. Tsao
Publikováno v:
Journal of Medicinal Chemistry. 52:3039-3046
3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one (17) is a high affinity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK(1)) receptor antagonist with a lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21762545018b32ec2dc16a2b6444d66
https://doi.org/10.1021/jm8016514
https://doi.org/10.1021/jm8016514
Autor:
Alana Upthagrove, Kimberly Krone, Jos H. Beijnen, Jan H.M. Schellens, A. C. Dubbelman, Eugene Tan, Serena Marchetti, Suraj Anand
Publikováno v:
Cancer chemotherapy and pharmacology. 70(5)
This study investigated the metabolism and excretion of dovitinib (TKI258), a tyrosine kinase inhibitor that inhibits fibroblast, vascular endothelial, and platelet-derived growth factor receptors, in patients with advanced solid tumors.Four patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6824f8de7dcf0f50564d83fd98a481a3
https://pubmed.ncbi.nlm.nih.gov/23010851
https://pubmed.ncbi.nlm.nih.gov/23010851